Dupilumab-associated ocular surface disease: incidence, management and long-term sequelae

• DOI: 10.1101/2020.06.16.20124909
• Publication Date: 2020-06-19T16:22:09Z
• Authors: Magdalena Z Popiela; Ramez Barbara; Andrew M J Turnbull; Emma Corden; Beatrice Suarez M...; Daniel O’Driscoll; Michael R Ardern-...; Parwez N Hossain
• Keywords: Dupilumab; Ciclosporin; Demographics

Abstract Objective To determine the incidence of ocular surface disease in patients with atopic dermatitis (AD) treated dupilumab at a tertiary, university hospital. describe features dupilumab-associated disease, establish need for treatment and report any long-term effects on surface. Methods A retrospective analysis consecutive AD between January 2017 August 2019 was undertaken. Data collected demographics, type features, natural history treatment. Results 50% (14/28) developed symptoms mean time onset 6.75 (+/- 6.1) weeks from starting dupilumab. 69% these (9/13) were diagnosed conjunctivitis - associated cicatrisation two periorbital skin changes four. Of nine, four had prior keratoconjunctivitis. All topical steroids; required additional ciclosporin drops. 67% (6/9) chronic inflammation requiring maintenance drops 16 6.9) months follow up. improvement their severity; only one patient discontinued due to side effects. Conclusion The rate 32%. Periorbital conjunctival noted association conjunctivitis. Ocular improved steroids but needed on-going Patients should be referred an ophthalmologist as large proportion develops inflammation.